Additional Relevant Details We will receive a flat 30% royalty on U.S. sales in an average of 22% on ex-U.S. sales. This level of royalty is the equivalent of owning half of the drug. Cipro DPI is targeting non-cystic fibrosis bronchiectasis or NCFB, the Phase 3 RESPIRE program features two 48-week multinational randomized placebo control studies with data expected in the second half of 2016. The market for Cipro DPI is estimated to be about $750 million and Nektar will receive an average 10% royalty on net sales.